Kadence Bio
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Reproductive/Sexual Health
Kadence Bio (kadencebio.com) is developing the first FDA-approved treatment for premature ejaculation (PE). Aim is to close the “intimacy gap,” roughly a 3x difference in time to climax between healthy men and women, closer to 10x for couples impacted by early ejaculation. PE is a large underserved market, the ambition is to do for climax control what Viagra did for erectile dysfunction. We are currently ahead of schedule in a Phase 2a efficacy trial for data readout in 2026. Pharmas and institutional biotech funds have indicated interest to transact pending positive data. Team is made up of repeat biotech founders with Nasdaq exits (CMPS, ATAI) and senior global pharma leaders including the current CMO at GSK and the former head of marketing for Viagra.
Company HQ City:
London
Company HQ State:
UK
Company HQ Country:
United Kingdom
Year Founded:
2021
Lead Product in Development:
KH-001, small molecule
CEO
John Boghossian, former VP Operations Compass Pathways (Nasdaq: CMPS)
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
December 2026
What is your next catalyst (value inflection) update?
Phase 2a clinical proof-of-concept data (lead asset)
Lead selection (pipeline assets)
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}